Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc. - ROEverified

2696.HK

Price:

$53.4

Market Cap:

$24.77B

Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications ...[Read more]

Industry

Biotechnology

IPO Date

2019-09-25

Stock Exchange

HKSE

Ticker

2696.HK

The ROE as of October 2026 (TTM) for Shanghai Henlius Biotech, Inc. (2696.HK) is 20.41%

According to Shanghai Henlius Biotech, Inc.’s latest financial reports and current stock price. The company's current ROE is 20.41%. This represents a change of 297.95% compared to the average of 5.13% of the last 4 quarters.

Shanghai Henlius Biotech, Inc. (2696.HK) Historical ROE (quarterly & annually)

How has 2696.HK ROE performed in the past?

The mean historical ROE of Shanghai Henlius Biotech, Inc. over the last ten years is 27.19%. The current 20.41% ROE has changed -24.93% with respect to the historical average. Over the past ten years (40 quarters), 2696.HK's ROE was at its highest in in the March 2018 quarter at 89.28%. The ROE was at its lowest in in the December 2022 quarter at -21.56%.

Quarterly (TTM)
Annual

Average

27.19%

Median

-21.88%

Minimum

-42.85%

Maximum

337.89%

Shanghai Henlius Biotech, Inc. (2696.HK) ROE by Quarter and Year

Discovering the peaks and valleys of Shanghai Henlius Biotech, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 41.93%

Maximum Annual ROE = 337.89%

Minimum Annual Increase = -158.62%

Minimum Annual ROE = -42.85%

Quarterly (TTM)
Annual
YearROEChange
202520.33%-25.32%
202427.23%9.31%
202324.91%-158.62%
2022-42.49%-0.83%
2021-42.85%37.94%
2020-31.06%41.93%
2019-21.88%-20.10%
2018-27.39%-108.11%

Shanghai Henlius Biotech, Inc. (2696.HK) Average ROE

How has 2696.HK ROE performed in the past?

The current ROE of Shanghai Henlius Biotech, Inc. (2696.HK) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

24.15%

5-year avg

-2.57%

10-year avg

27.19%

Shanghai Henlius Biotech, Inc. (2696.HK) ROE vs. Peers

How is 2696.HK’s ROE compared to its peers?

Shanghai Henlius Biotech, Inc.’s ROE is greater than Mabwell-b (-179.83%), less than Innovent Biologics, Inc. (6.06%), less than Mabpharm Limited (48.25%), greater than SinoMab BioScience Limited (-41.81%), less than Edding Genor Group Holdings Limited (10.99%), less than HBM Holdings Limited (21.50%), less than 3SBio Inc. (30.16%), greater than Akeso, Inc. (-10.86%), greater than Nanjing Leads Biolabs Co Ltd (-23.34%),

Build a custom stock screener for Shanghai Henlius Biotech, Inc. (2696.HK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Shanghai Henlius Biotech, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Shanghai Henlius Biotech, Inc. (2696.HK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Shanghai Henlius Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Shanghai Henlius Biotech, Inc.'s ROE?

How is the ROE calculated for Shanghai Henlius Biotech, Inc. (2696.HK)?

What is the highest ROE for Shanghai Henlius Biotech, Inc. (2696.HK)?

What is the 3-year average ROE for Shanghai Henlius Biotech, Inc. (2696.HK)?

What is the 5-year average ROE for Shanghai Henlius Biotech, Inc. (2696.HK)?

How does the current ROE for Shanghai Henlius Biotech, Inc. (2696.HK) compare to its historical average?